The prognostic blood biomarker proadrenomedullin for outcome prediction in patients with chronic obstructive pulmonary disease (COPD): A qualitative clinical review

Clinical Chemistry and Laboratory Medicine

Volumn 53, Issue 4, 2015, Pages 521-539

  Schuetz, Philipp ^a,b   Marlowe, Robert J ^c   Mueller, Beat ^b  

^a University Department of Internal Medicine   (Switzerland)

^b Division of General Internal and Emergency Medicine   (Switzerland)

^c Spencer Fontayne Corporation   (United States)

Author keywords

6 min walk test (6MWT); cardiopulmonary exercise testing; chronic obstructive pulmonary disease (COPD); mortality prediction; proadrenomedullin (ProADM); risk stratification

Indexed keywords

ADRENOMEDULLIN; ANTIBIOTIC AGENT; BIOLOGICAL MARKER; PREDNISOLONE; PROADRENOMEDULLIN; PROTEIN PRECURSOR;

6 MIN WALK TEST; BLOOD SAMPLING; CARDIOPULMONARY EXERCISE TEST; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL DECISION MAKING; CLINICAL RESEARCH; DEMOGRAPHY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; EXPERIMENTAL LOCOMOTOR ACTIVITY TEST; HUMAN; INTERVENTION STUDY; LUNG DISEASE; LUNG MINUTE VOLUME; MORTALITY; OUTCOME ASSESSMENT; PATIENT MONITORING; PHYSICAL ACTIVITY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QUALITATIVE RESEARCH; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; STRESS; SYSTEMATIC REVIEW; ANIMAL; BLOOD; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

BACTERIA (MICROORGANISMS);

ADRENOMEDULLIN; ANIMALS; BIOMARKERS; HUMANS; PROGNOSIS; PROTEIN PRECURSORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK ASSESSMENT;

EID: 84925784414     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2014-0748     Document Type: Review

References (95)

1. Global Initiative for Chronic Obstructive Pulmonary. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2014. Available at: http://www. goldcopd.org/guidelines-global-strategy-for-diagnosis-manage-ment.html. Accessed on July 18, 2014.
2. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004;350:1005-12.
3. Puhan M.A., Garcia-Aymerich J, Frey M, ter Riet G, Anto JM, Agusti AG, et al. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. Lancet 2009;374: 704-11.
4. Steer J, Gibson J, Bourke SC. The DECAF Score: predicting hospital mortality in exacerbations of chronic obstructive pulmonary disease. Thorax 2012;67:970-6.
5. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J 2009;34:648-54.
6. Koutsokera A, Stolz D, Loukides S, Kostikas K. Systemic biomarkers in exacerbations of COPD: the evolving clinical challenge. Chest 2012;141:396-405.
7. Kostikas K, Bakakos P, Papiris S, Stolz D, Celli BR. Systemic bio-markers in the evaluation and management of COPD patients: are we getting closer to clinical application? Curr Drug Targets 2013;14:177-91.
8. Faner R, Tal-Singer R, Riley JH, Celli B, Vestbo J, Macnee W, et al. Lessons from ECLIPSE: a review of COPD biomarkers. Thorax 2014;69:666-72.
9. Casaburi R, Celli B, Crapo J, Criner G, Croxton T, Gaw A, et al. The COPD Biomarker Qualification Consortium (CBQC). COPD 2013;10:367-77.
10. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Measurement of midregional proadrenomedullin in plasma with an immunolu-minometric assay. Clin Chem 2005;51:1823-9.
11. Christ-Crain M, Morgenthaler NG, Struck J, Harbarth S, Bergmann A, Muller B. Mid-regional pro-adrenomedullin as a prognostic marker in sepsis: an observational study. Crit Care 2005;9:R816-24.
12. Wang RL, Kang FX. Prediction about severity and outcome of sepsis by pro-atrial natriuretic peptide and pro-adrenomedullin. Chin J Traumatol 2010;13:152-7.
13. Suberviola B, Castellanos-Ortega A, Llorca J, Ortiz F, Iglesias D, Prieto B. Prognostic value of proadrenomedullin in severe sepsis and septic shock patients with community-acquired pneumonia. Swiss Med Wkly 2012;142:w13542.
14. Guignant C, Voirin N, Venet F, Poitevin F, Malcus C, Bohe J, et al. Assessment of pro-vasopressin and pro-adrenomedullin as predictors of 28-day mortality in septic shock patients. Intensive Care Med 2009;35:1859-67.
15. Roch A. Increased levels of pro-AVP and pro-ADM in septic shock patients: what could it mean? Intensive Care Med 2009;35:1827-9.
16. Hagag AA, Elmahdy HS, Ezzat AA. Prognostic value of plasma pro-adrenomedullin and antithrombin levels in neonatal sepsis. Indian Pediatr 2011;48:471-3.
17. Oncel MY, Dilmen U, Erdeve O, Ozdemir R, Calisici E, Yurttutan S, et al. Proadrenomedullin as a prognostic marker in neonatal sepsis. Pediatr Res 2012;72:507-12.
18. Pezzilli R, Barassi A, Pigna A, Morselli-Labate AM, Imbrogno A, Fabbri D, et al. Time course of proadrenomedullin in the early phase of septic shock. A comparative study with other proin-flammatory proteins. Panminerva Med 2012;54:211-7.
19. Akpinar S, Rollas K, Alagoz A, Segmen F, Sipit T. Performance evaluation of MR-proadrenomedullin and other scoring systems in severe sepsis with pneumonia. J Thorac Dis 2014;6:921-9.
20. Potocki M, Breidthardt T, Reichlin T, Morgenthaler NG, Bergmann A, Noveanu M, et al. Midregional pro-adrenomedullin in addition to b-type natriuretic peptides in the risk stratification of patients with acute dyspnea: an observational study. Crit Care 2009;13:R122.
21. Maisel A, Mueller C, Nowak R, Peacock WF, Landsberg JW, Ponikowski P, et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 2010;55:2062-76.
22. Dieplinger B, Gegenhuber A, Kaar G, Poelz W, Haltmayer M, Mueller T. Prognostic value of established and novel biomarkers in patients with shortness of breath attending an emergency department. Clin Biochem 2010;43:714-9.
23. Maisel A, Mueller C, Nowak RM, Peacock WF, Ponikowski P, Mockel M, et al. Midregion prohormone adrenomedullin and prognosis in patients presenting with acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 2011;58:1057-67.
24. Shah RV, Truong QA, Gaggin HK, Pfannkuche J, Hartmann O, Januzzi JL Jr. Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea. Eur Heart J 2012;33:2197-205.
25. Cinar O, Cevik E, Acar A, Kaya C, Ardic S, Comert B, et al. Evaluation of mid-regional pro-atrial natriuretic peptide, procalcitonin, and mid-regional pro-adrenomedullin for the diagnosis and risk stratification of dyspneic ED patients. Am J Emerg Med 2012;30:1915-20.
26. Travaglino F, Russo V, De Berardinis B, Numeroso F, Catania P, Cervellin G, et al. Thirty and ninety days mortality predictive value of admission and in-hospital procalcitonin and mid-regional pro-adrenomedullin testing in patients with dyspnea. Results from the VERyfing DYspnea trial. Am J Emerg Med 2014;32:334-41. [Epub 25 Feb 2014].
27. Christ-Crain M, Morgenthaler NG, Stolz D, Muller C, Bingisser R, Harbarth S, et al. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397]. Crit Care 2006;10:R96.
28. Huang DT, Angus DC, Kellum JA, Pugh NA, Weissfeld LA, Struck J, et al. Midregional proadrenomedullin as a prognostic tool in community-acquired pneumonia. Chest 2009;136:823-31.
29. Kruger S, Ewig S, Giersdorf S, Hartmann O, Suttorp N, Welte T. Cardiovascular and inflammatory biomarkers to predict short-and long-term survival in community-acquired pneumonia: results from the German Competence Network, CAPNETZ. Am J Respir Crit Care Med 2010;182:1426-34.
30. Schuetz P, Wolbers M, Christ-Crain M, Thomann R, Falconnier C, Widmer I, et al. Prohormones for prediction of adverse medical outcome in community-acquired pneumonia and lower respiratory tract infections. Crit Care 2010;14:R106.
31. Guertler C, Wirz B, Christ-Crain M, Zimmerli W, Mueller B, Schuetz P. Inflammatory responses predict long-term mortality risk in community-acquired pneumonia. Eur Respir J 2011;37:1439-46.
32. Albrich WC, Dusemund F, Ruegger K, Christ-Crain M, Zimmerli W, Bregenzer T, et al. Enhancement of CURB65 score with proadre-nomedullin (CURB65-A) for outcome prediction in lower respiratory tract infections: derivation of a clinical algorithm. BMC Infect Dis 2011;11:112.
33. Bello S, Lasierra AB, Minchole E, Fandos S, Ruiz M.A., Vera E, et al. Prognostic power of proadrenomedullin in community-acquired pneumonia is independent of aetiology. Eur Respir J 2012;39:1144-55.
34. Hartmann O, Schuetz P, Albrich WC, Anker SD, Mueller B, Schmidt T. Time-dependent Cox regression: serial measurement of the cardiovascular biomarker proadrenomedullin improves survival prediction in patients with lower respiratory tract infection. Int J Cardiol 2012;161:166-73.
35. Renaud B, Schuetz P, Claessens YE, Labarere J, Albrich W, Mueller B. Proadrenomedullin improves Risk of Early Admission to ICU score for predicting early severe community-acquired pneumonia. Chest 2012;142:1447-54.
36. Kolditz M, Halank M, Schulte-Hubbert B, Bergmann S, Albrecht S, Hoffken G. Copeptin predicts clinical deterioration and persistent instability in community-acquired pneumonia. Respir Med 2012;106:1320-8.
37. Sarda Sanchez M, Hernandez JC, Hernandez-Bou S, Teruel GC, Rodriguez JV, Cubells CL. Pro-adrenomedullin usefulness in the management of children with community-acquired pneumonia, a preliminary prospective observational study. BMC Res Notes 2012;5:363.
38. Courtais C, Kuster N, Dupuy AM, Folschveiller M, Jreige R, Bargnoux AS, et al. Proadrenomedullin, a useful tool for risk stratification in high Pneumonia Severity Index score community acquired pneumonia. Am J Emerg Med 2013; 31:215-21.
39. Stolz D, Christ-Crain M, Morgenthaler NG, Miedinger D, Leuppi J, Muller C, et al. Plasma pro-adrenomedullin but not plasma pro-endothelin predicts survival in exacerbations of COPD. Chest 2008;134:263-72.
40. Zuur-Telgen MC, Brusse-Keizer MG, VanderValk PD, van der Palen J, Kerstjens HA, Hendrix MG. Stable-state midrange-proadrenomedullin level is a strong predictor of mortality in COPD patients. Chest 2014;145:534-51.
41. Grolimund E, Kutz A, Marlowe RJ, Vögeli A, Alan M, Christ-Crain M, et al. Long-term prognosis in COPD exacerbation: role of bio-markers, clinical variables and exacerbation type COPD. J Chron Obstruct Pulmon Dis 2014 (in press).
42. Stolz D, Kostikas K, Blasi F, Boersma W, Milenkovic B, Lacoma A, et al. Adrenomedullin refines mortality prediction by the BODE index in COPD: the "BODE-A" index. Eur Respir J 2014;43:397-408.
43. Jehn M, Schindler C, Meyer A, Tamm M, Koehler F, Witt C, et al. Associations of daily walking activity with biomarkers related to cardiac distress in patients with chronic obstructive pulmonary disease. Respiration 2013;85:195-202.
44. Stolz D, Boersma W, Blasi F, Louis R, Milenkovic B, Kostikas K, et al. Exertional hypoxemia in stable COPD is common and predicted by circulating proadrenomedullin. Chest 2014;146:328-38.
45. Zurek M, Maeder MT, Brutsche MH, Luthi A, Twerenbold R, Freese M, et al. Midregional pro-adrenomedullin and copeptin: exercise kinetics and association with the cardiopulmonary exercise response in comparison to B-type natriuretic peptide. Eur J Appl Physiol 2014;114:815-24.
46. Kitamura K, Kangawa K, Kawamoto M, Ichiki Y, Nakamura S, Matsuo H, et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 1993;192:553-60.
47. Kitamura K, Sakata J, Kangawa K, Kojima M, Matsuo H, Eto T. Cloning and characterization of cDNA encoding a precursor for human adrenomedullin. Biochem Biophys Res Commun 1993;194:720-5.
48. Kitamura K, Kangawa K, Eto T. Adrenomedullin and PAMP: discovery, structures, and cardiovascular functions. Microsc Res Tech 2002;57:3-13.
49. Kitamura K, Kangawa K, Kojima M, Ichiki Y, Matsuo H, Eto T. Complete amino acid sequence of porcine adrenomedul-lin and cloning of cDNA encoding its precursor. FEBS Lett 1994;338:306-10.
50. Temmesfeld-Wollbruck B, Hocke AC, Suttorp N, Hippenstiel S. Adrenomedullin and endothelial barrier function. Thromb Hae-most 2007;98:944-51.
51. Hao SL, Yu ZH, Qi BS, Luo JZ, Wang WP. The antifibrosis effect of adrenomedullin in human lung fibroblasts. Exp Lung Res 2011;37:615-26.
52. Marinoni E, Pacioni K, Sambuchini A, Moscarini M, Letizia C, R DII. Regulation by hypoxia of adrenomedullin output and expression in human trophoblast cells. Eur J Obstet Gynecol Reprod Biol 2011;154:146-50.
53. Martinez A, Miller MJ, Unsworth EJ, Siegfried JM, Cuttitta F. Expression of adrenomedullin in normal human lung and in pulmonary tumors. Endocrinology 1995;136:4099-105.
54. Elsasser TH, Kahl S. Adrenomedullin has multiple roles in disease stress: development and remission of the inflammatory response. Microsc Res Tech 2002;57:120-9.
55. Xue Y, Taub P, Iqbal N, Fard A, Clopton P, Maisel A. Mid-region pro-adrenomedullin adds predictive value to clinical predictors and Framingham risk score for long-term mortality in stable outpatients with heart failure. Eur J Heart Fail 2013;15:1343-9.
56. Allaker RP, Grosvenor PW, McAnerney DC, Sheehan BE, Srikanta BH, Pell K, et al. Mechanisms of adrenomedullin antimicrobial action. Peptides 2006;27:661-6.
57. Matsui H, Shimosawa T, Itakura K, Guanqun X, Ando K, Fujita T. Adrenomedullin can protect against pulmonary vascular remodeling induced by hypoxia. Circulation 2004;109:2246-51.
58. Smith JG, Newton-Cheh C, Hedblad B, Struck J, Morgenthaler NG, Bergmann A, et al. Distribution and correlates of midregional proadrenomedullin in the general population. Clin Chem 2009;55:1593-5.
59. Pfeil U, Aslam M, Paddenberg R, Quanz K, Chang CL, Park JI, et al. Intermedin/adrenomedullin-2 is a hypoxia-induced endothelial peptide that stabilizes pulmonary microvas-cular permeability. Am J Physiol Lung Cell Mol Physiol 2009;297:L837-45.
60. Di Paola R, Talero E, Galuppo M, Mazzon E, Bramanti P, Motilva V, et al. Adrenomedullin in inflammatory process associated with experimental pulmonary fibrosis. Respir Res 2011;12:41.
61. Qi JG, Ding YG, Tang CS, Du JB. Chronic administration of adre-nomedullin attenuates hypoxic pulmonary vascular structural remodeling and inhibits proadrenomedullin N-terminal 20-pep-tide production in rats. Peptides 2007;28:910-9.
62. Li W, Kong QY, Zhao CF, Zhao F, Li FH, Xia W, et al. Adrenomedul-lin and adrenotensin regulate collagen synthesis and proliferation in pulmonary arterial smooth muscle cells. Braz J Medi Biological Res 2013;46:1047-55.
63. Vizza CD, Letizia C, Sciomer S, Naeije R, Della Rocca G, Di Roma A, et al. Increased plasma levels of adrenomedullin, a vasoactive peptide, in patients with end-stage pulmonary disease. Regul Pept 2005;124:187-93.
64. Lewis LK, Smith MW, Yandle TG, Richards AM, Nicholls MG. Adrenomedullin(1-52) measured in human plasma by radioim-munoassay: plasma concentration, adsorption, and storage. Clin Chem 1998;44:571-7.
65. Goode KM, Nicholls R, Pellicori P, Clark AL, Cleland JG. The in vitro stability of novel cardiovascular and sepsis biomarkers at ambient temperature. Clin Chem Lab Med 2014;52:911-8.
66. Stolz D, Christ-Crain M, Bingisser R, Leuppi J, Miedinger D, Muller C, et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 2007;131:9-19.
67. Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. J Am Med Assoc 2009;302:1059-66.
68. Albrich WC, Ruegger K, Dusemund F, Schuetz P, Arici B, Litke A, et al. Biomarker-enhanced triage in respiratory infections: a proof-of-concept feasibility trial. Eur Respir J 2013;42:1064-75.
69. Mockel M, Searle J, Hartmann O, Anker SD, Peacock WF, Wu AH, et al. Mid-regional pro-adrenomedullin improves disposition strategies for patients with acute dyspnoea: results from the BACH trial. Emerg Med J 2013;30:633-7.
70. Caruhel P, Mazier C, Kunde J, Morgenthaler NG, Darbouret B. Homogeneous time-resolved fluoroimmunoassay for the measurement of midregional proadrenomedullin in plasma on the fully automated system B.R.A.H.M.S KRYPTOR. Clin Biochem 2009;42:725-8.
71. Neumann JT, Tzikas S, Funke-Kaiser A, Wilde S, Appelbaum S, Keller T, et al. Association of MR-proadrenomedullin with cardiovascular risk factors and subclinical cardiovascular disease. Atherosclerosis 2013;228:451-9.
72. Maeder MT, Brutsche MH, Arenja N, Socrates T, Reiter M, Meissner J, et al. Biomarkers and peak oxygen uptake in patients with chronic lung disease. Respiration 2010;80: 543-52.
73. Chen ZH, Kim HP, Sciurba FC, Lee SJ, Feghali-Bostwick C, Stolz DB, et al. Egr-1 regulates autophagy in cigarette smoke-induced chronic obstructive pulmonary disease. PLoS One 2008;3:e3316.
74. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994;47:1245-51.
75. Pencina MJ, D'Agostino RB, Sr., Demler OV. Novel metrics for evaluating improvement in discrimination: net reclassification and integrated discrimination improvement for normal variables and nested models. Stat Med 2012;31:101-13.
76. Zudaire E, Martinez A, Cuttitta F. Adrenomedullin and cancer. Regul Pept 2003;112:175-83.
77. Khan SQ, O'Brien RJ, Struck J, Quinn P, Morgenthaler N, Squire I, et al. Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study. J Am Coll Cardiol 2007;49:1525-32.
78. Masson S, Latini R, Carbonieri E, Moretti L, Rossi MG, Ciricugno S, et al. The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trial. Eur J Heart Fail 2010;12:338-47.
79. Wild PS, Schnabel RB, Lubos E, Zeller T, Sinning CR, Keller T, et al. Midregional proadrenomedullin for prediction of cardiovascular events in coronary artery disease: results from the AtheroGene study. Clin Chem 2012;58:226-36.
80. Tzikas S, Keller T, Ojeda FM, Zeller T, Wild PS, Lubos E, et al. MR-proANP and MR-proADM for risk stratification of patients with acute chest pain. Heart 2013;99:388-95.
81. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111-7.
82. Eggers KM, Venge P, Lindahl B, Lind L. Associations of mid-regional pro-adrenomedullin levels to cardiovascular and metabolic abnormalities, and mortality in an elderly population from the community. Int J Cardiol 2013;168:3537-42.
83. Bhandari SS, Davies JE, Struck J, Ng LL. Influence of confounding factors on plasma mid-regional pro-adrenomedullin and mid-regional pro-A-type natriuretic peptide concentrations in healthy individuals. Biomarkers 2011;16:281-7.
84. Brouwers FP, de Boer RA, van der Harst P, Struck J, de Jong PE, de Zeeuw D, et al. Influence of age on the prognostic value of mid-regional pro-adrenomedullin in the general population. Heart 2012;98:1348-53.
85. 1. Respir Med 2008;102 Suppl 1:S27-35.
86. Divo M, Cote C, de Torres JP, Casanova C, Marin JM, Pinto-Plata V, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;186:155-61.
87. Celli BR, Locantore N, Yates J, Tal-Singer R, Miller BE, Bakke P, et al. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;185:1065-72.
88. Schuetz P, Litke A, Albrich WC, Mueller B. Blood biomarkers for personalized treatment and patient management decisions in community-acquired pneumonia. Curr Opin Infect Dis 2013;26:159-67.
89. Schuetz P, Koller M, Christ-Crain M, Steyerberg E, Stolz D, Muller C, et al. Predicting mortality with pneumonia severity scores: importance of model recalibration to local settings. Epidemiol Infect 2008;136:1628-37.
90. Albrich WC, Dusemund F, Bucher B, Meyer S, Thomann R, Kuhn F, et al. Effectiveness and safety of procalcitonin-guided antibiotic therapy in lower respiratory tract infections in "real life": an international, multicenter poststudy survey (ProREAL). Arch Intern Med 2012;172:715-22.
91. Schuetz P, Albrich W, Christ-Crain M, Chastre J, Mueller B. Procalcitonin for guidance of antibiotic therapy. Expert Rev Anti Infect Ther 2010;8:575-87.
92. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003;58:377-82.
93. Duvoix A, Dickens J, Haq I, Mannino D, Miller B, Tal-Singer R, et al. Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease. Thorax 2013;68:670-6.
94. Albrich WC, Ruegger K, Dusemund F, Bossart R, Regez K, Schild U, et al. Optimised patient transfer using an innovative multidisciplinary assessment in Kanton Aargau (OPTIMA I): an observational survey in lower respiratory tract infections. Swiss Med Wkly 2011;141:w13237.
95. Pencina MJ, D'Agostino RB, Sr., D'Agostino RB, Jr., Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008;27:157-72; discussion 207-12.